Trial :


Age :

18 - 75 years

Trial length :

4 follow up visits

Info :

No overnight stays required

This study is investigating a new potential medicine for the treatment of psoriasis.  Psoriasis is an inflammatory skin disease that affects more than 125 million people worldwide. Current treatments for patients with psoriasis are based on controlling the symptoms. Anti-inflammatory drugs such as corticosteroids and vitamin-D analogues are the main prescribed topical treatments. The study drug is defined as a vaccine – as it is used to stimulate the production of antibodies. In laboratory testing it has demonstrated the reduction of inflammation. 

To be eligible you must:

  • A healthy male or female participant with psoriasis
  • Aged 18 – 75 years
  • BMI between 18.5 kg/m2 to 38 kg/m2

If you meet the criteria for this study and would like more information, register below or call 1800 727 874.